CNTA Centessa Pharmaceuticals plc Insider Trading

Chief People Officer Karen M. Anderson sold 41,076 shares of CNTA at $30.12 (total $1.2M), reducing stake 39.8% to 62,085 shares.

Anderson sold 41,076 shares at $30.12 on 2026-03-26, the fourth sale within a 10-day span (prior sales on 2026-03-17, 2026-03-16, and twice on 2026-03-13). This concentrated selling activity at prices near the 52-week high of $29.91 represents a substantial reduction in her holdings (from 103,161 to 62,085 shares, a -39.8% decrease). Her cross-ticker track record shows 8 prior sells with a 100.00% well-timed rate at the 90-day mark (average 90d return -29.4%), and at CNTA specifically, her sole measurable historical sale on 2025-02-10 posted -35.2% 90-day return. Centessa faces significant operational headwinds: the company reported $0.00 latest-quarter revenue, a net loss of $-54,891,000.00, and -100.0% annual revenue growth, with a $3.9B market cap despite ongoing unprofitability. The rapid succession of sales by the Chief People Officer amid deteriorating fundamentals and at elevated valuations warrants investor attention.

Chief People Officer Karen M. Anderson sold 74,811 shares (54.6% of holdings) at $28.19 avg on 2026-03-16/17 ($2.1M)

Anderson executed 2 separate sales totaling 74,811 shares for $2,109,179.58 on March 16–17, reducing her stake from 136,896 shares to 62,085 shares—a 54.6% reduction in holdings. Her cross-ticker track record shows 6 prior sells with a 100.00% well-timed rate at the 90-day mark, and at CNTA specifically, all 3 prior measurable sales (2025-02-10, 2025-02-07, 2024-03-25) were well-timed, with 90-day declines ranging from -21.9% to -35.2%. Against this backdrop, the magnitude of this divestment (nearly 75K shares) by the Chief People Officer is notable. The company is unprofitable with $-54,891,000.00 net income and -100.0% annual revenue growth, creating a fundamental backdrop where pattern-consistent insider selling warrants investor attention—particularly given the concentration and speed of this reduction relative to her prior activity.

CNTA Chief Business Officer Weinhoff sells 73,196 shares for $1.9M amid ongoing losses

Gregory M Weinhoff, Chief Business Officer, executed 2 separate sales totaling 73,196 shares for $1,927,131.05 at blended average price $26.33 on 2026-03-13. The sale reduced his holdings by 52.6%, from 139,121 shares to 65,925 shares. This material reduction in stake occurs in context of significant company stress: Centessa reported net income of $-54,891,000.00 and zero revenue in the latest quarter, with full-year net income negative, while the stock sits -12.0% from its 52-week high despite recent +11.8% 30-day momentum. A sale of this scale by a C-level executive during a period of unprofitability and zero revenue signals reduced executive exposure to company risk, particularly given the magnitude of the position reduction.

CPO Karen M. Anderson sold 120,029 shares (120.0K) at blended average $26.25 for $3,150,672.76 (-65.9% of holdings)

Anderson Karen M., Chief People Officer, executed 2 separate sales totaling 120,029 shares for $3,150,672.76, reducing her holdings by -65.9% from 182,114 shares to 62,085 shares. Her prior 4 sales at CNTA all posted negative 90-day returns (ranging -21.9% to -35.2%), establishing a consistent pattern where the stock subsequently declined after her sales. Against current company fundamentals (Revenue $0.00 latest quarter, Net income $-54,891,000.00, Annual revenue growth -100.0%), this substantial divestiture represents a material reduction in her stake at an unprofitable biotech. The timing and scale of this sale, coupled with her prior well-timed exit pattern at this ticker (4 of 4 prior sells negative at 90 days), warrant close monitoring of the company's near-term trajectory and insider confidence indicators.

Chief Legal Officer sells 39,961 shares (40.0K) across 2 transactions for $1,004,917.61 in Centessa; post-sale holdings 117,645 shares, -25.4% reduction

HUSSAIN IQBAL J, Chief Legal Officer, executed 2 separate sales totaling 39,961 shares (40.0K shares) for $1,004,917.61 on 2026-01-30 and 2026-02-02 at blended average price $25.15, reducing his holdings from 157,606 shares to 117,645 shares. The -25.4% reduction in holdings is material. His prior 3 sells at CNTA have shown mixed timing outcomes: two sales in September 2025 saw substantial 90-day gains (+30.0% and +47.5%), while a December 2024 sale produced only +4.6% over 90 days—none were well-timed by the metric that measures whether the stock fell after the sale. The company remains unprofitable with $-54,891,000 net income in the latest period and zero revenue, characteristics relevant to context though not determinative of insider motivation. Current price of $25.48 reflects a +7.6% move in the prior 30 days but remains -14.8% from the 52-week high, placing these sales at a point where the stock had already recovered from earlier lows.

CTO Bush Tia L sold 40,000 CNTA shares at $28.00 on 2025-11-17 (total $1.1M); stock now at $28.36, up 64.1% in 90 days.

Bush Tia L, Chief Technology & Quality Officer, divested 40,000 shares (24.8% of her pre-transaction holdings) at $28.00, reducing her stake from 161.5K to 121.5K shares. The sale occurred at the 52-week high of $28.36, and the stock has appreciated 64.1% over 90 days—suggesting the sell was not well-timed for capturing further gains. Her prior CNTA trades show mixed outcomes: a recent sell on 2025-11-12 is unmeasured, while three earlier 2025 sales posted modest positive returns (0.6% to 14.2% at 30 days), with none yet reaching measurable 90-day marks. Against this backdrop, Centessa remains unprofitable (net income of $-54.9M annually) with zero quarterly revenue, making fundamental execution risk material despite the stock's recent rally.

CTO Tia L. Bush sells 40,000 CNTA shares at $26.00; stock rallies 43.9% in 90 days post-sale

Bush, Chief Technology & Quality Officer, sold 40,000 shares (40.0K shares) at $26.00 on 2025-11-12 for $1,040,000.00 ($1.0M), reducing her position by -24.8% from 161,503 to 121,503 shares. The timing of this sale appears suboptimal: the stock has appreciated 43.9% over the 90-day period since the transaction and currently trades near its 52-week high of $26.70. Her prior sales at CNTA have shown mixed timing, with a 14.2% gain in the 30 days following one September trade, yet none of her prior sells at this ticker achieved positive outcomes at the 90-day measurement point. The company remains unprofitable with a net loss of $-54,891,000.00 ($-54.9M) in its most recent full fiscal year, making the subsequent equity rally difficult to attribute to operational improvements.

Chief Technology & Quality Officer Tia L Bush sells 35,000 CNTA shares at $24.00 (52-week high), reducing stake by 22.4%

Tia L Bush, Chief Technology & Quality Officer at Centessa Pharmaceuticals, sold 35,000 shares at $24.00 on 2025-09-24, reducing her holdings from 156.5K to 121.5K shares. The sale occurred at the 52-week high ($23.97), and she has initiated two prior sales at this ticker within days (2025-09-10 and 2025-09-09), suggesting a coordinated reduction sequence. Against a backdrop of an unprofitable company with -$50.3M net income in the latest quarter and -100.0% annual revenue growth, the timing and scale of this executive's stake reduction warrant investor attention. The stock's recent momentum (+41.0% over 30 days, +83.8% over 90 days) creates urgency to understand whether the sale reflects upcoming company announcements or carries other significance beyond the price levels achieved.

CTO Bush Tia L sold 49,792 shares in 2 transactions for $1,045,840 at avg $21.00; stock now $22.67, up 32.5% in 30 days

Bush Tia L, Chief Technology & Quality Officer, executed 2 separate sales totaling 49,792 shares for $1,045,840.00 at a blended average price of $21.00, reducing holdings by 29.1% from 171,295 shares to 121,503 shares. The stock has since rallied to $22.67, up 32.5% over the past 30 days and 83.1% over 90 days, placing it near its 52-week high of $22.71. Notably, this sale occurred against a backdrop of recent strong price momentum and a company with zero current-quarter revenue and a $-50,343,000 net loss in its most recent full fiscal year. The combination of a material position reduction by a senior technology officer concurrent with significant recent gains, paired with the company's unprofitable fundamentals, merits attention to whether underlying operational or strategic developments influenced the timing.

General Counsel Hussain Iqbal J sold 40,000 CNTA shares for $840,102 across 2 transactions; stock up 32.5% in 30 days and 83.1% in 90 days.

Hussain Iqbal J, General Counsel at Centessa Pharmaceuticals, executed 2 separate sales on 2025-09-09 and 2025-09-10, totaling 40,000 shares for $840,102.00 at a blended average price of $21.00, reducing his holdings from 145.4K to 105.4K shares (a -27.5% reduction). The stock has appreciated significantly since the transaction, rising 32.5% over 30 days and 83.1% over 90 days, now trading at $22.67 and near its 52-week high of $22.71. His prior sale at this ticker on 2024-12-16 yielded a 90-day return of +4.6%, indicating his last sellside transaction preceded a period of stock appreciation rather than decline. The company remains unprofitable with net income of $-50,343,000.00 and zero revenue in the latest quarter, though the stock's recent momentum contrasts sharply with its fundamental distress.